Related content

Erratum to: Are ABO and Rh blood groups new genetic risk factors for endometriosis?

By Daliri K.   Tabei S.   Amini A.   Derakhshankhah H.  

Archives of Gynecology and Obstetrics, Vol. 289, Iss. 4, 2014-04 ,pp. : 921-921

Springer Publishing Company

Access to resources Recommend Favorite

Blood leukocyte subsets are modulated in patients with endometriosis

By Gagne D.   Rivard M.   Page M.   Shazand K.   Hugo P.   Gosselin D.  

Fertility and Sterility, Vol. 80, Iss. 1, 2003-07 ,pp. : 43-53

Elsevier

Access to resources Recommend Favorite

Gn-RH agonists and ovarian endometriosis

By Descamps P.   Lansac J.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 79, Iss. 2, 1998-08 ,pp. : 143-144

Elsevier

Access to resources Recommend Favorite

Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelinacetate. Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur(R)), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome

By Regidor P.-A.   Regidor M.   Kato K.   Bier U.W.   Buhler K.   Schindler A.E.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 73, Iss. 2, 1997-06 ,pp. : 153-160

Elsevier

Access to resources Recommend Favorite

Early treatment of endometriosis with GnRH-agonists: impact on time to recurrence

By Schindler A.E.   Foertig P.   Kienle E.   Regidor P.A.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 93, Iss. 2, 2000-12 ,pp. : 123-125

Elsevier

Access to resources Recommend Favorite